Abstract
Previous studies have demonstrated that Sickle Cell Disease (SCD) can be corrected in mouse models by transduction of hematopoietic stem cells with lentiviral vectors containing anti-sickling globin genes followed by transplantation of these cells into syngeneic recipients. Although self-inactivating (SIN) lentiviral vectors with or without insulator elements should provide a safe and effective treatment in humans, some concerns about insertional mutagenesis persist. An ideal correction would involve replacement of the sickle globin gene (β S ) with a normal copy of the gene (β A ). We recently derived embryonic stem (ES) cells from a novel knockin mouse model of SCD and tested a protocol for correcting the sickle mutation by homologous recombination. In this paper, we demonstrate the replacement of the human β S -globin gene with a human β A -globin gene and the derivation of mice from these cells. The animals produce high levels of normal human hemoglobin (HbA) and the pathology associated with SCD is corrected. Hematological values are restored to normal levels and organ pathology is ameliorated. These experiments provide a foundation for similar studies in human ES cells derived from sickle cell patients. Although efficient methods for production of human ES cells by somatic nuclear transfer must be developed, the data in this paper demonstrate that sickle cell disease can be corrected without the risk of insertional mutagenesis.
Introduction__________________________________________________
Sickle Cell Disease (SCD) is an autosomal recessive disorder that affects a significant proportion (approximately 1 in 500 individuals) of the African American population. Hispanic, Arabic, Mediterranean and some Asian populations are also affected. Over 300,000 individuals worldwide and over 70,000 in the U.S. suffer from the disease. The molecular basis for sickle cell disease is an A to T transversion in the 6th codon of the human β-globin gene 1, 2 . This simple transversion changes a polar glutamic acid residue to a non-polar valine in the β S -globin chain on the surface of HbS (α 2 β S 2 ) tetramers. The valine creates a hydrophobic projection that fits into a natural hydrophobic pocket formed on Hb tetramers after deoxygenation 3, 4 . The interaction of tetramers results in the formation of HbS polymers/fibers that cause red blood cells to become rigid and nondeformable and to occlude small capillaries [5] [6] [7] [8] [9] [10] . These vasoocclusive events cause severe tissue damage that can result in strokes, splenic infarction, kidney failure, liver and lung disorders, painful crises and other complications. Cycles of erythrocyte sickling also cause the cells to become fragile, and lysis produces chronic anemia.
Sickle cell disease is normally a relatively benign disorder in the first few months of life because human fetal hemoglobin (HbF) has potent anti-sickling properties. HbF, which comprises 70-90% of total hemoglobin at birth, is gradually replaced by HbS during the first few months of life. Rising HbS levels result in the onset of disease between 3 and 6 months of age. We recently produced a knockout/transgenic mouse model that mimics this switch from HbF to HbS. The LCR γ-β S transgene in these animals was designed to switch hemoglobins after birth [11] [12] [13] rather than before birth [14] [15] [16] [17] [18] [19] For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From as observed in animals produced with cosmid, BAC or YAC transgenes. The LCR γ-β S transgenic animals are relatively healthy at birth and then develop severe anemia when the switch to HbS is completed at approximately 3 weeks of age. More recently, we utilized the same γ-β S configuration to produce a knockin mouse model of sickle cell disease (unpublished) as discussed further below. These animals complete the switch of human hemoglobins (HbF to HbS) after birth and develop the same severe anemia as the knockout/transgenic mice during the first week of life. We derived embryonic stem (ES) cells from these sickle knockin mice for the studies presented below.
Two groups have corrected sickle cell disease (SCD) in mouse models by transduction of hematopoietic stem cells with lentiviral vectors containing anti-sickling globin genes followed by transplantation of these cells into syngeneic recipients 20, 21 . Although self-inactivating (SIN) lentiviral vectors with or without insulator elements should provide a safe and effective treatment for hemoglobinopathies 22 , some concerns about insertional mutagenesis persist 23 . If viral integration inhibits a tumor suppressor gene or activates an oncogene, leukemia can result. Recent studies of children transplanted with retrovirally transduced hematopoietic cells in France reveal that this outcome can occur 24 . An approach that bypasses this problem is replacement of the sickle globin gene (β was digested with SalI to produce an 8.7 kb -383 γ-β A DNA fragment. The SalI sites were changed to ClaI by adding adaptors and the 8.7 kb ClaI fragment was subcloned into pBluescript. An HSV thymidine kinase (TK) gene, which is driven by a phosphoglycerate kinase (PGK) promoter, was digested with XbaI and a 2.0 kb XbaI fragment was isolated. This fragment was subcloned into the plasmid pTR18 that contains XhoI and SalI sites on either side of XbaI. This plasmid was digested with XhoI and SalI to generate a 2.0 kb XhoI/SalI fragment. Another plasmid, containing 1.7 kb of mouse 5' homology, a floxed PGK/Hygro gene and 7 kb of mouse 3' homology was linearized with SalI and the 13.3 kb DNA fragment was isolated from an agarose gel. The 2.0 kb XhoI/SalI fragment containing PGK/TK was inserted into the SalI site of pTR401. The resulting plasmid was then digested with ClaI, which cuts between the mouse 5' homology and the floxed PGK/Hygro gene, and the 8.7 kb γ-β 
ES cell culture and homologous recombination to repair DNA lesion
The production of a novel, knockin mouse model of sickle cell disease and the derivation of ES cells from these mice will be described elsewhere (unpublished). The -383 γ-β A DNA construct described above was linearized by NotI digestion and electroporated into the knockin sickle ES cells (hα/hα, -1400 γ-β S /-1400 γ-β S ). The cells were plated onto mitomycin C treated mouse embryonic fibroblasts (MEF) in Dulbecco's Modification of Eagle's Medium (DMEM, MediaTech Inc., Herndon, VA) supplemented with 16.7% characterized Fetal Bovine Serum (FBS, HyClone, Logan, UT), 1X Nucleosides, 2mM LGlutamine, 1X nonessential amino acids, 50 IU/mL penicillin, 50µg/mL streptomycin, 0.1mM β-mercaptoethanol, and 1000U/mL leukemia inhibitory factor (LIF). Positive/negative selection in hygromycin (125 µg/mL) and gancyclovir (2 µM) was used to enrich for homologous recombinants 25 . DNA isolated from individual ES cell colonies was analyzed by PCR. Homologous recombinants were identified with primers 1 and 2 to identify correct 5' sequences (primer 1 is outside of the vector homology region) and with primers 5 and 6 to identify correct 3' sequences (primer 6 is outside of the vector homology region). PCR with primers 3 and 4 followed by Bsu36I digestion was used to distinguish β 
Blastocyst Injection and Globin Protein Analysis
Correctly targeted ES cell lines were injected into C57BL/6 blastocysts. Chimeric males obtained from these injected blastocysts were mated with hα/hα, -1400 γ-β Fifty microliters of whole blood was washed in 500 µL PBS. Cell pellets were resuspended in 100 µL lysis solution (5 mM Sodium phosphate, 0.5 mM EDTA, pH 7.4) and incubated on ice for 15 minutes. One tenth volume of 10% NaCl was added and the sample was centrifuged at maximum speed in an Eppendorf microfuge. Approximately 1 µL of the supernatant was analyzed on an isoelectric focusing (IEF) gel. IEF was performed using the Isothermal Controlled Electrophoresis system (Fisher Scientific, Pittsburgh, PA) with precast agarose IEF gels (RESOLVE from PerkinElmer, Finland). Hemoglobin bands were quantitated by densitometry with a BioRad (Hercules, CA) GS-800 scanner using Quantity One software.
Hematological Indices and Histopathology
Blood was collected from anesthetized animals into Microtainer EDTA collection tubes. RBC count was measured on a HemaVet 1700 (CDC Technology, Oxford, CT) hematology analyzer. Hemoglobin concentration was determined spectrophotometrically after conversion to cyanmethemoglobin with Drabkin's reagent (Sigma, St. Louis, MO). Before determining the hemoglobin concentration, red cell membranes were pelleted at 14,000 RPM for 5 minutes in an Eppendorf microfuge. Packed Cell Volume (PCV) was measured with a JorVet J503 (Jorgenson Laboratories Systems, Loveland, CO) microhematocrit centrifuge. Reticulocyte counts were determined by flow cytometry after staining with Thiazole Orange. Urine osmolality was measured with the Wescor Vapro Vapor Pressure Osmometer 5520 (Logan, UT) after food and water were withheld from the mice for sixteen hours. Tissues preparations from the spleen, liver, and kidney were fixed in 70% alcoholic formalin, embedded in paraffin, sectioned and stained with hematoxylin-eosin stain by standard methods. ________________________________________________________________________
Results

Production of a human β
A -globin gene targeting construct
We recently produced a knockin mouse model of sickle cell disease by replacing the mouse α-globin genes with a human α-globin gene (hα/hα) and by replacing the mouse β-globin genes with human A γ-and β (Fig. 1b) .
Replacement of the human β
S -globin gene with the human β
A -globin gene in ES cells derived from knockin sickle mice
The targeting construct described above was electroporated into knockin sickle ES cells and the cells were grown in hygromycin and gancyclovir for two weeks. One hundred and thirteen colonies were picked and homologous recombinants were identified by PCR of genomic DNA. In 16 of the 113 colonies (14.2%), the β S -globin gene was successfully replaced with the β A -globin gene. In one of the 16 colonies, recombination at the 5' end occurred upstream of the -383 γ sequence; therefore, the replacement allele contained the -383
A γ-globin gene promoter (Fig. 1b and c, 5 ' PCR, lane 2; 1.8 kb PCR product). In the remaining 15 colonies, recombination at the 5' end occurred downstream of the -383 γ sequence; therefore, the replacement allele maintained the -1400 γ promoter (Fig. 1b and c (Fig. 1b and c) . Homologous recombination at the 3' end of all 16 colonies was correct (Fig. 1b and c, 3 We also measured hematological values in the corrected mice and compared these values to the numbers obtained for sickle and control animals. These data are presented in Table 1 
Discussion
We have recently produced a new mouse model of sickle cell disease by replacing the mouse β-globin genes with a 9.7 kb DNA fragment containing the human A γ-globin gene (5.6 kb) and a human β S -globin gene (4.1 kb) . The γ-and β S -globin genes contain 1,400 bp and 815 bp of 5' flanking sequence, respectively. Mouse α-globin genes were also replaced with a human α-globin gene. At birth, these knockin sickle mice continue to synthesize significant amounts of human HbF. During the first week after birth, the animals switch to greater than 99% HbS and develop severe disease. We linked the human γ-and β S -globin genes in a relatively small fragment because we previously found that this design resulted in a HbF to HbS switch that mimicked the switch in human sickle patients [11] [12] [13] . Larger fragments derived from cosmids, YACs and BACs switch hemoglobins in utero [14] [15] [16] [17] [18] [19] , and this early switch from HbF to high levels of HbS results in a high rate of perinatal mortality. The γ-β S fragment in the knockin sickle mice described above is identical to the configuration of the transgene in our previous knockout/transgenic sickle mice, and globin gene switching is similar in these two models.
We derived ES cells from these animals and tested a gene replacement protocol for correcting the disease. This approach avoids random insertions that are characteristic of viral gene therapy approaches. Although relatively few insertional mutations have been observed in viral gene therapy studies, the SCID gene therapy trials in France demonstrated that leukemic cell clones can arise from insertional activation of LMO-2 24 , and experiments in non-human primates have suggested that insertional inactivation of BCL-2A1 can result in acute myeloid leukemia 26 . The risk of mutagenesis is a consequence of random insertion of one or more copies of the viral vector in a large number of cells. If 2 to 3 million CD34+ cells per kilogram of body weight are transduced and transplanted, a 50 kg patient would receive 100 million cells and, potentially, 100 million different viral insertions. Although the number of reported, insertional mutations after viral gene therapy has been low, the large number of insertion sites remains a concern.
The gene replacement strategy described in this paper avoids the risk of insertional mutagenesis. The defective β-globin gene (β S ) was replaced with a normal copy of the gene (β A ) in ES cells, and cells derived from a single corrected clone were fully characterized before transplantation. In the present study, the cells were transplanted into blastocysts and hematopoietic stem cells (HSC) derived from these cells in vivo produced corrected red blood cells that did not sickle in recipients; consequently, the anemia and organ pathology of the disease was cured. Of course, translation of this approach to human patients would involve in vitro derivation of HSC [27] [28] [29] from corrected, patientspecific ES cells. This approach would provide corrected, fully characterized, syngeneic HSC for intravenous transplantation, and red blood cells derived from these HSC in vivo would not sickle.
The application of this approach to patients with sickle cell disease requires successful derivation of patient-specific ES cells by somatic cell nuclear transfer (SCNT). The recent retractions of two papers 30, 31 describing the derivation of human ES cells by this technique is a significant setback for the field. However, the feasibility of the approach has been demonstrated in animal models 32, 33 . Therefore, with additional basic research, there is a reasonable expectation that patient-specific, nuclear transfer ES (ntES) cells can be derived in the future. Correction of the sickle mutation by gene replacement in ntES cells derived from skin fibroblasts (or in skin fibroblasts before nuclear transfer) should provide a means to produce corrected cells that can be differentiated into HSC in vitro and transplanted into patients. Red blood cells derived from these HSC in vivo will not sickle, and this treatment should cure the disease. For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From
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